United Therapeutics Corporation
UTHR
$477.07
-$2.88-0.60%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.27B | 1.24B | 1.21B | 1.20B | 1.11B |
| Total Depreciation and Amortization | 82.50M | 79.70M | 77.30M | 72.50M | 66.50M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 168.70M | 165.70M | 145.80M | 119.70M | 106.90M |
| Change in Net Operating Assets | 33.30M | -116.20M | -22.00M | -60.20M | -147.70M |
| Cash from Operations | 1.56B | 1.37B | 1.41B | 1.33B | 1.14B |
| Capital Expenditure | -434.30M | -300.30M | -283.20M | -246.50M | -238.50M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -89.20M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -12.60M | -402.40M | -199.60M | 663.70M | 910.20M |
| Cash from Investing | -446.90M | -702.70M | -482.80M | 417.20M | 582.50M |
| Total Debt Issued | 200.00M | 200.00M | -- | -- | -- |
| Total Debt Repaid | -600.00M | -700.00M | -400.00M | -400.00M | -400.00M |
| Issuance of Common Stock | 109.70M | 101.50M | 135.50M | 160.10M | 141.80M |
| Repurchase of Common Stock | -1.02B | -21.20M | -16.10M | -1.01B | -1.01B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -11.50M | -11.50M | 0.00 | -2.70M | -2.70M |
| Cash from Financing | -1.32B | -431.20M | -280.60M | -1.25B | -1.27B |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -213.80M | 237.40M | 648.40M | 489.50M | 446.20M |